Triface from edema reviews

Pharmachologic effect:
Trifas (torasemide) is a derivative ofsulfamonlantranilic acid. Refers to loop diuretics. The name of the group of diuretics is related to the location of the "target" for their action in the nephron loop. Like other drugs in this group, torasemide enters the lumen of the nephron and binds to the cotransporter Na-K-Cl, which is a protein found in the apical membranes of the cells of the thick segment of its ascending knee. As a result, the active transport of Na, K, and Cl ions from the lumen of the tubule is suppressed. Thanks to this mechanism, up to 20% of filtered sodium is excreted by the kidneys. Accordingly, the reabsorption of water decreases.
Torasemide promotes increased renal functionblood flow. This is due to an increase in prostacyclin synthesis, as well as by activation of the kallikrein-kinin system. This property of all loop diuretics explains their effectiveness with reduced glomerular filtration.
An increase in prostacyclin synthesis also causes an expansion of the venous bed and a decrease in preload in the left ventricle.
KHS of the body does not affect the diuretic effect of the drug.
The diuretic effect of torasemide significantly increases with increasing dose.

A feature of torasemide is its anti-aldosterone action, which leads to a smaller loss of potassium ions than furosemide.
Another important feature of torasemide isthe absence of a "rebound phenomenon" - the enhancement of the reabsorption of sodium ions after the cessation of the diuretic effect of the drug due to the activation of the renin-angiotensin system.
The interior of the torasemide is rapidly absorbed from thethe digestive tract. The intake process does not affect the intake process. The concentration in the plasma reaches a maximum after one or two hours. Bioavailability of the drug is 80-91%. After intravenous administration, the effect develops rapidly enough, reaching a maximum after 1-3 hours and remaining for 12 hours.
Active (M1 and M3) and inactive (M5) metabolites are formed in the liver.
About 80% of the dose of thorasemide taken is excretedkidneys. The remainder is excreted with bile. The half-life is three to four hours. In the presence of kidney failure, this indicator does not change.

Indications for use:
Triphas (torasemide) is indicated for:
- edematic syndrome on the background of kidney and liver diseases, heart failure;
- arterial hypertension;
acute left ventricular failure (solution).

Mode of application:
Tablets are taken in the morning. One day is enough for a single appointment.
When treating edematous syndrome, the daily dose of Trifas is 5 mg. If necessary, it can be up to 20 mg.
The recommended initial daily dose for renal failure is 20 mg and, if necessary, it can be up to 200 mg.
With AH therapy, the daily dose of Triphas is 2.5 mg and can be maximally increased to 5 mg (further increase is not advisable).

The solution is administered intravenously. The usual single dose in the treatment of edematous syndrome is 0.01 g (2 ml Triface 20). Perhaps its two- sometimes four-fold increase. In the latter case, the duration of therapy should not exceed three days.
When Trefas treats pulmonary edema, a single doseof the solution is 0.02 g (4 ml of Triface 20). In case of insufficient effect, repeated injections in the indicated dose are performed with a thirty minute interval. The total amount of the drug should not exceed 0.1 g.

Side effects:
- Leukopenia, anemia, thrombocytopenia;
- hypokalemia, hypovolemia, hypomagnesemia, hyperglycemia, hyperlipidemia, hyperuricemia, metabolic alkalosis;
- Atrial hypotension, tendency to thrombosis;
- dry mouth, loss of appetite, pancreatitis, diarrhea, increased activity of liver enzymes, constipation, vomiting;
acute urinary retention, azotemia;
- headache, drowsiness, weakness, dizziness, paresthesia, convulsions, confusion;
- deafness, noise in the ears, visual disturbances;
- Photosensitivity, skin itch, eczema.

- Anuria;
- growth of azotemia;
- hepatic coma or precoma;
- arterial hypotension;
- arrhythmia;
- Pregnancy;
- age younger than 18 years;
- lactation period;
- Hypersensitivity.

Trifas is contraindicated.

Interaction with other drugs:
When co-administered with laxative drugs, as well as with mineral and glucocorticoids, the risk of hypokalemia increases.
When caused by the use of Trifas hypokalemia or hypomagnesemia, the sensitivity of the heart muscle to cardiac glycosides increases.
Trifas potentiates the effect of hypotensive drugs, theophylline, curare-like muscle relaxants.
Potentiates the toxic effects of cephalosporins, aminoglycosides, cisplatin, lithium, salicylates.
Weaken the action of antidiabetic drugs, adrenomimetics.
Probenecid reduces the effects of Triface.

Clinical manifestations - intensive diuresis withdevelopment of dehydration and impaired metabolism of electrolytes. There is confusion, arterial hypotension, hypokalemia (with the possible development of arrhythmias), alkalosis. Treatment: cancellation of the drug, infusion therapy with correction of KHS and electrolyte disturbances.

Form of issue:
- A solution of 0.01 g in ampoules containing 2.0 ml of No. 5;
- a solution of 0.2 g for infusion, in ampoules with a capacity of 20.0 ml of No. 5;
- a solution of 0.01 g in ampoules containing 2.0 ml of No. 5;
- a solution of 0.2 g for infusion, in ampoules with a capacity of 20.0 ml of No. 5;
- tablets containing 0.01 g of preparation No. 30, No. 100 and No. 50;
- tablets containing 0.2 g of preparation No. 10, No. 100, No. 20 and No. 30;
- tablets to 0,005 g № 30, № 100, № 20, № 50.

Storage conditions:
Protection from exposure to light is required, temperature ≤ 25 ° C.

Diver, Trigrim.

Torasemide 0.01 g and 0.005 g.
In addition - corn starch, magnesium stearate, lactose monohydrate, silicon dioxide.

Torasemide 0.2 g.
Additionally - crospovidone, lactose monohydrate, povidone K25, microcrystalline cellulose, magnesium stearate.

Torasemide 0.02 g or 0.2 g.